The investigators aim to study the effect of liquid oxygen therapy (4l/min, nasal) )in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).
- Minimum 18 years of age
Written informed consent
Patients with diagnosed pulmonary arterial hypertension (PAH), distal chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD) with emphysema, COPD without emphysema, or interstitial lung disease
Former desaturation under exercise defined as SpO2-decrease >3%
- Severe hypoxemia needing supplemental oxygen therapy defined as PaO2 < 6.9 kPa
Inability or contraindications to undergo the investigated intervention
Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, walk disability etc.
Silvia Ulrich Somaini
Lead sponsor
University of Zurich
Sponsor institution